{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T21:48:28Z","timestamp":1793915308495,"version":"4.8.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T00:00:00Z","timestamp":1694044800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019556","name":"EANM","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019556","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.eururo.2023.09.003","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T15:42:48Z","timestamp":1695397368000},"page":"49-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer"],"prefix":"10.1016","volume":"85","author":[{"given":"Daniela-Elena","family":"Oprea-Lager","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"MacLennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bjartell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igle","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Eberlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke","family":"Gillessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Heskamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Iagaru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara Alicja","family":"Jereczek-Fossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolanta","family":"Kunikowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marnix","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Nanni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe M.","family":"O'Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valeria","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evis","family":"Sala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Sathekge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Sosnowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Tombal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Treglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tunariu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Walz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Yakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudi","family":"Dierckx","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Fanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.09.003_b0005","unstructured":"IARC. Data visualization tools for exploring the global cancer burden in 2020. https:\/\/gco.iarc.fr\/today\/home."},{"key":"10.1016\/j.eururo.2023.09.003_b0010","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","article-title":"Recent global patterns in prostate cancer incidence and mortality rates","volume":"77","author":"Culp","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.09.003_b0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nrurol.2016.251","article-title":"The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA","volume":"14","author":"Fleshner","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2023.09.003_b0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13020359","article-title":"Global trends of latent prostate cancer in autopsy studies","volume":"13","author":"Kimura","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2023.09.003_b0025","doi-asserted-by":"crossref","first-page":"e696","DOI":"10.1016\/S1470-2045(18)30604-1","article-title":"Consensus on molecular imaging and theranostics in prostate cancer","volume":"19","author":"Fanti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2023.09.003_b0030","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.09.003_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap consortium: Building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.eururo.2023.09.003_b0040","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.eururo.2023.09.003_b0045","article-title":"The Rand\/UCLA appropriateness method user\u2019s manual","author":"Fitch","year":"2001","journal-title":"Rand"},{"key":"10.1016\/j.eururo.2023.09.003_b0050","unstructured":"Microsoft Corporation. Microsoft Excel. 2018. https:\/\/office.microsoft.com\/excel."},{"key":"10.1016\/j.eururo.2023.09.003_b0055","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jclinepi.2017.05.006","article-title":"The GRADE Working Group clarifies the construct of certainty of evidence","volume":"87","author":"Hultcrantz","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2023.09.003_b0060","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. Part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.09.003_b0065","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II\u20142020 update: treatment of relapsing and metastatic prostate cancer","volume":"79","author":"Cornford","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.09.003_b0070","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2022.04.002","article-title":"Management of patients with advanced prostate cancer: report from the Advanced Prostate Cancer Consensus Conference 2021","volume":"82","author":"Gillessen","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.09.003_b0075","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.eururo.2022.11.002","article-title":"Management of patients with advanced prostate cancer. Part I: intermediate-\/high-risk and locally advanced disease, biochemical relapse, and side effects of hormonal treatment: report of the Advanced Prostate Cancer Consensus Conference 2022","volume":"83","author":"Gillessen","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.09.003_b0080","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.euo.2020.11.002","article-title":"The role of magnetic resonance imaging and positron emission tomography\/computed tomography in the primary staging of newly diagnosed prostate cancer: a systematic review of the literature","volume":"4","author":"Abrams-Pompe","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.09.003_b0085","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s00259-020-05025-0","article-title":"PET\/MRI in prostate cancer: a systematic review and meta-analysis","volume":"48","author":"Evangelista","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.09.003_b0090","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3390\/diagnostics11030552","article-title":"Diagnostic role of 18F-PSMA-1007 PET\/CT in prostate cancer staging: a systematic review","volume":"11","author":"Awenat","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.eururo.2023.09.003_b0095","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/bco2.73","article-title":"M1a prostate cancer: results of a Dutch multidisciplinary consensus meeting","volume":"2","author":"Aluwini","year":"2021","journal-title":"BJUI Compass"},{"key":"10.1016\/j.eururo.2023.09.003_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers12082153","article-title":"Diagnostic performance of PET imaging using different radiopharmaceuticals in prostate cancer according to published meta-analyses","volume":"12","author":"Annunziata","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.eururo.2023.09.003_b0105","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1007\/s00330-022-09095-6","article-title":"Magnetic resonance imaging for prostate cancer recurrence: it\u2019s time for precision diagnostic with Prostate Imaging for Recurrence Reporting (PI-RR) score","volume":"33","author":"Panebianco","year":"2023","journal-title":"Eur Radiol"},{"key":"10.1016\/j.eururo.2023.09.003_b0110","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.euo.2021.02.003","article-title":"Positron emission tomography and whole-body magnetic resonance imaging for metastasis-directed therapy in hormone-sensitive oligometastatic prostate cancer after primary radical treatment: a systematic review","volume":"4","author":"Farolfi","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.eururo.2023.09.003_b0115","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.eururo.2023.09.003_b0120","first-page":"1288","article-title":"NCCN Guidelines\u00ae insights: prostate cancer, version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.eururo.2023.09.003_b0125","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fonc.2020.00055","article-title":"Imaging for metastasis in prostate cancer: a review of the literature","volume":"10","author":"Turpin","year":"2020","journal-title":"Front Oncol"},{"key":"10.1016\/j.eururo.2023.09.003_b0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41391-022-00581-y","article-title":"Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and 68Ga-PSMA-11 PET\/MRI in the detection of biochemical recurrence of prostate cancer: summary of head-to-head comparison studies","volume":"26","author":"Huo","year":"2023","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2023.09.003_b0135","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2023.09.003_b0140","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.3390\/biomedicines9081042","article-title":"177Lu-PSMA radioligand therapy is favorable as third-line treatment of patients with metastatic castration-resistant prostate cancer. A systematic review and network meta-analysis of randomized controlled trials","volume":"9","author":"von Eyben","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.eururo.2023.09.003_b0145","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","article-title":"A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177\u2013labeled prostate-specific membrane antigen\u2013targeted radioligand therapy in metastatic castration-resistant prostate cancer","volume":"80","author":"Sadaghiani","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.09.003_b0150","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1002\/pros.24325","article-title":"177Lu-PSMA radioligand therapy effectiveness in metastatic castration-resistant prostate cancer: an updated systematic review and meta-analysis","volume":"82","author":"Sadaghiani","year":"2022","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2023.09.003_b0155","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1200\/JCO.21.02440","article-title":"Considerations on integrating prostate-specific membrane antigen positron emission tomography imaging into clinical prostate cancer trials by National Clinical Trials Network Cooperative Groups","volume":"40","author":"Sch\u00f6der","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2023.09.003_b0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/MNM.0000000000001535","article-title":"Dosimetry in Lu-177-PSMA-617 prostate-specific membrane antigen targeted radioligand therapy: a systematic review","volume":"43","author":"Nautiyal","year":"2022","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.eururo.2023.09.003_b0165","doi-asserted-by":"crossref","first-page":"663","DOI":"10.3390\/diagnostics11040663","article-title":"Concordance between response assessment using prostate-specific membrane antigen pet and serum prostate-specific antigen levels after systemic treatment in patients with metastatic castration resistant prostate cancer: a systematic review and meta-analysis","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/j.eururo.2023.09.003_b0170","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1007\/s00259-022-06089-w","article-title":"PSMA PET\/CT: joint EANM procedure guideline\/SNMMI procedure standard for prostate cancer imaging 2.0","volume":"50","author":"Fendler","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.09.003_b0175","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","article-title":"E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET","volume":"48","author":"Ceci","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.eururo.2023.09.003_b0180","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2023.09.003_b0185","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.eururo.2017.10.027","article-title":"PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of PSMA-targeted PET imaging studies","volume":"73","author":"Rowe","year":"2018","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823030920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823030920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:37Z","timestamp":1759583617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823030920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0302283823030920"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.09.003","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}